Skip to main content
Premium Trial:

Request an Annual Quote

SpIntellx, ICura Strike Precision Cancer Medicine Partnership

NEW YORK — Computational pathology firm SpIntellx has partnered with contract research organization ICura to offer new spatial analytics products for precision cancer treatment, the companies said on Thursday.

The alliance combines SpIntellx's software-as-a-service offerings for precision pathology with ICura's technical expertise in multiplex assay development and omics data analysis to develop products combining genomic, proteomic, transcriptomic, and clinical data to explore spatial heterogeneity in the tumor microenvironment.

"Together with ICura, we will be able to improve prediction accuracies and drive personalized therapeutic options for selecting optimal therapeutics based on insights into spatial tumor biology of individual patients and their potential outcomes," SpIntellx CEO Dusty Majumdar said in a statement.

Additional terms of the deal between the Pennsylvania-based companies were not disclosed.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.